Despite positive clinical data, copyright's Vyndamax, a therapy for hereditary transthyretin-mediated amyloidosis (hATTR), is experiencing substantial resistance from pharmacy benefit managers. Such companies are often creating barriers to coverage, like high expense criteria and PA that hinder c